This review examines several of the recently introduced wound care products that have been put forward as treatment modalities for the diabetic foot ulcer. Discussed are the results of clinical trials with the platelet-derived growth factor, becaplermin, the tissue-engineered products Dermagraft and Apligraf, and Hyaff which is an ester of hyaluronic acid. In patients with an infected foot ulcer, encouraging results were obtained with the granulocyte-colony stimulating factor, Filgrastim.

Becaplermin↗

PubMedDate not supplied

A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer.

A Markov model was developed to determine the cost of treating patients with stage IIIB or IV metastatic breast cancer with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) and dexrazoxane (administered after six courses of FAC) versus FAC alone. The primary end point in our economic study was cost per cardiac event avoided. Cost per life-year saved was also calculated, even though the survival advantage needs to be confirmed in follow-up studies. The model incorporated the direct medical costs of treating patients with chemotherapy, as well as the costs associated with treatment of any cardiac events that occurred. Data were collected for this analysis from several sources, including completed clinical trials on FAC plus dexrazoxane versus FAC plus placebo (obtained from two patient groups randomized at different time points), a panel of three oncologists, and a panel of three cardiologists. Analyses showed that therapy with dexrazoxane costs $5661.77 per cardiac event prevented. Sensitivity analyses on model variables were performed and showed that the basic results of the model did not change when parameters were varied. The clinical efficacy and cost-effectiveness of dexrazoxane as shown by the results of the current study encourage further investigation of the uses of dexrazoxane in other populations and against other comparators.

Antibiotics, Antineoplastic↗

PubMedDate not supplied

Hepatic excretion of cholecystopaques introduced into the canine jejunum.

The biliary excretion of five oral cholecystopaques was measured following their introduction into the jejunum of bile fistula dogs. The mean maximal iodine concentration in the bile ranged form a low of 2.2 +/- 0.55 mg per ml following a dose of 33 mg of iodine per kg of iopanoic acid to a high of 12.9 +/- 1.4 mg per ml after the same dose of sodium ipodate. Cumulative excretion at the end of three hours was over five times greater with sodium ipodate in comparison to ipoanoic acid. It is felt that the best explanation of this date is the ability of the more water soluble media to pass through the unstirred water layer of the intestine.

Animals↗

PubMedDate not supplied

Factors in the intestinal absorption of oral cholecystopaques.

Interest in the pharmacokinetics of cholecystopaques initially centered on transport from blood to bile. The data obtained in this effort have been valuable and have shown that the maximal iodine concentration achievable in the bile is quite similar for all of the currently available compounds. This concentration is, of course, dose dependent. the transport of contrast material from the bowel to the blood has been shown to be quite variable. Considerable progress was made in understanding this. The tremendous differences in absorption of iopanoic acid depending upon the pH of the administered solution was an initial revelation. The development of the concept that there is a water layer through which the cholecystopaque must pass before reaching the lipid membrane of the intestinal cell has added clarity to understanding the difference in absorption between water-soluble and water-insoluble cholecystopaques. A complete knowledge of what might enhance or inhibit absorption is not known. There is beginning to be an understanding of how intestinal dose relates to plasma levels. This should lead to an optimal dose-timing scheme for each cholecystopaque. The basic assumption is that the highest iodine concentration in the gallbladder leads to the most accurate cholecystography. If this is true, the gallbladder needs to be offered bile at the maximum concentrations during the period preceding filming. To accomplish this, the appropriate plasma level necessary for maximum excretion is needed. Experimental data suggest that our current clinical methods in regard to dose and dose timing need revision to optimize cholecystography. This revision needs to take place with a careful look at toxicity. Accepting the present premise that oral cholecystography can be improved, perhaps without a significant increase in morbidity, a fundamental question to be asked is: is it worth it?

Animals↗

PubMedDate not supplied

Gallbladder density and iodine concentration in humans during oral cholecystography. A comparison of iopanoic acid and iopronic acid.

A comparison of two oral cholecystopaques, iopanoic acid (Telepaque) and iopronic acid (Oravue), was performed using normal volunteers. Using a double-blind crossover design, comparisons were made between the degree of gallbladder opacification and the amount of iodine recovered from the gallbladder. Bile was collected via a double lumen intestinal tube before, during, and after stimulating gallbladder contraction. There were no differences between the two agents in terms of opacification or iodine concentration. Only 19% of the administered dose of either agent was recovered, and the maximum iodine concentration in bile was 10 mg I/ml. The results suggest that this technique has merit for future comparative studies of agents concentrated in the gallbladder.

Administration, Oral↗

PubMedDate not supplied

Catastrophic weight loss after vertical banded gastroplasty: malnutrition and neurologic alterations.

The case of a patient with severe vomiting and very rapid weight loss following vertical banded gastroplasty (VBG) (almost 50% of original weight in 11 months) and who suffered severe neurological and nutritional disorders is reported. All abnormal findings with the exception of nystagmus, disappeared during enteral nutritional support with a complete diet and vitamin supplementation. The alterations found in this case may have been related to the very rapid weight loss, which resulted in protein calorie malnutrition and, probably, in one or more vitamin deficiencies. This complication may be preventable by early nutritional intervention in subjects undergoing gastric reduction surgery and who exhibit very rapid weight loss and intractable vomiting.

Adult↗

PubMedDate not supplied

Medicinal leech therapy: an overview (continuing education credit).

Leech therapy has made a comeback as a legitimate form of therapy for treating venous congestion following grafts and replants. Complications caused directly by leech therapy are minimal, as are the risks, while the benefits can be revascularization of replanted tissue. Nurses are integral in preparing patients for leech therapy.

Adult↗

PubMedDate not supplied

Anatomic applications of xenon-enhanced CT scanning: visual image analysis and brain-blood partition coefficient studies in man.

The inhalation of nonradioactive xenon, an inert gas that diffuses freely across the blood-brain barrier, resulted in brain enhancement which was quantitated and visualized by computed tomography (CT). Serial CT scans obtained during the buildup and equilibrium phase of xenon inhalation were used in a numerical and visual analysis of xenon accumulation in multiple selected gray- and white-matter regions in 12 patients. The calculated brain-blood partition coefficient (lambda) in normal gray matter was 0.92 +/- 0.11 and in normal white matter, 1.38 +/- 0.14. Asymmetries and delays in xenon enhancement were often visually apparent. The estimated partition coefficient was diminished more with cerebral infarction, intracerebral hematoma, and vasogenic edema than with hypoxic encephalopathy or glioblastoma multiforme. An increase in the rate of xenon accumulation was apparent by visual inspection of the motor cortex contralateral to complex hand movements. Technical factors and potential difficulties in conducting xenon-enhanced CT studies are discussed.

Adolescent↗

PubMedDate not supplied

Safety of contrast media in cerebral angiography: iopamidol vs. methylglucamine iothalamate.

A randomized double-blind study was performed in 27 patients to compare the clinical safety, incidence of pain and warmth, and film quality produced by iopamidol and Conray-60 in selective cerebral angiography. No complications or adverse reactions occurred in either group. Iopamidol was significantly less painful than was methylglucamine iothalamate for common carotid artery injections and caused significantly less heat in both common carotid and internal carotid artery injections. Film quality and diagnostic accuracy were excellent in both groups. These results, when viewed in conjunction with laboratory data demonstrating the decreased neurotoxicity of nonionic contrast agents, suggest that iopamidol is an important advance in the development of angiographic contrast media.

Adult↗

PubMedDate not supplied

Clinical trial of iopamidol for lumbosacral myelography.

The results of the initial North American trial of the nonionic, water-soluble contrast medium iopamidol for lumbosacral myelography are reported. The iopamidol was easily visualized by fluoroscopy during introduction, and the radiographic quality of all 12 conventional myelographic examinations was excellent. The diagnoses were herniated nucleus pulposus (seven), traumatic dislocation (one), metastasis (one), and normal (three). One patient had a repeat myelogram with a different hydrosoluble contrast medium 2 months after his iopamidol examination and surgery and showed no radiographic evidence of arachnoiditis. The adverse reactions were all mild and transient: headache (four cases), nausea (two), and leg pain (one). There were no diaphoresis, fever, seizures, hallucinations, agitation, or vital sign changes. Electrocardiography, hematology, and blood chemistries were all normal. In two patients, electroencephalogram changes, three to four bursts of diffuse intermittent rhythmic delta activity with no spiking, were present at 6 hr with return to normal at 24 hr.

Clinical Trials as Topic↗